View Older Stories View More Recent Stories

Jan 13, 2026 04:30PM Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
Jan 12, 2026 08:04AM Praxis plans two drug applications by mid-February, raises $1.5 billion
Jan 12, 2026 08:00AM Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
Jan 9, 2026 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 8, 2026 04:45PM Praxis appoints two board directors and promotes two executives
Jan 8, 2026 04:45PM Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
Dec 29, 2025 08:01AM FDA grants breakthrough therapy designation to Praxis drug for essential tremor
Dec 29, 2025 08:00AM Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
Dec 11, 2025 08:02AM Praxis plans to file NDA for relutrigine in rare epilepsies by early 2026
Dec 11, 2025 08:00AM Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
Dec 9, 2025 04:01PM Praxis gets FDA agreement to simplify elsunersen trial design
Dec 9, 2025 04:01PM Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
Dec 8, 2025 08:00AM Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
Dec 4, 2025 04:12PM Praxis stops EMBOLD study early after relutrigine shows efficacy
Dec 4, 2025 04:10PM Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Dec 4, 2025 04:01PM Praxis receives FDA alignment on ulixacaltamide NDA submission plans
Dec 4, 2025 04:01PM Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
Dec 3, 2025 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 24, 2025 04:01PM Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
Nov 20, 2025 04:01PM Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Nov 6, 2025 08:00AM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2025 04:01PM Praxis Precision Medicines to Participate in Upcoming Investor Conferences
Nov 5, 2025 08:00AM Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Nov 4, 2025 08:00AM Praxis plans early 2026 NDA filing for relutrigine after FDA alignment
Nov 4, 2025 08:00AM Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
Oct 16, 2025 07:01AM Praxis reports positive phase 3 results for essential tremor drug
Oct 16, 2025 07:00AM Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
Oct 2, 2025 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 4, 2025 04:01PM Praxis Precision Medicines to Participate in September Investor Conferences
Sep 3, 2025 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 29, 2025 08:00AM Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Aug 25, 2025 04:01PM Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
Aug 6, 2025 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 5, 2025 06:09PM Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Aug 4, 2025 08:24PM Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Aug 4, 2025 08:30AM Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Aug 4, 2025 08:10AM Praxis reports positive seizure reduction results from vormatrigine trial
Aug 4, 2025 08:00AM Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine
Jul 29, 2025 08:00AM Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
Jul 17, 2025 08:01AM Praxis receives FDA breakthrough therapy designation for relutrigine
Jul 17, 2025 08:00AM Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Jul 2, 2025 05:00PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 4, 2025 05:00PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 20, 2025 08:00AM Praxis Precision Medicines to Participate in Upcoming Conferences
May 5, 2025 08:07AM Praxis Precision Medicines (PRAX) Highlights DEE Clinical Program Updates at Virtual Investor Event
May 5, 2025 08:00AM Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
May 2, 2025 05:00PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 2, 2025 08:30AM Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
Apr 8, 2025 08:00AM Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies
Apr 3, 2025 05:00PM Praxis Precision Medicines to Participate in Upcoming April Conferences
View More Recent Stories View Older Stories